TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03745989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
Study: NCT00954473

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01703715

Intervention type: DEVICE
Intervention: The Hydrant
Description: The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant.
Study: NCT01144286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arasertaconazole nitrate
Description: Arasertaconazole nitrate pessary, placebo pessary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arasertaconazole nitrate
Description: Arasertaconazole nitrate pessary, placebo pessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single dose
Study: NCT00565617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy, Epidural cortical stimulation
Description: Epidural cortical stimulation
Study: NCT03503526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receptive music therapy
Description: 12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
Study: NCT00735605

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFD
Description: The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDPR
Description: A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BTX A
Description: A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
Study: NCT03383237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg/d,q.d.,p.o.
Study: NCT02951468

Intervention type: PROCEDURE
Intervention: LCP plus iliac crest autograft
Description: After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
Study: NCT03885479

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens
Description: An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens
Description: An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
Study: NCT03824496

Intervention type: DIAGNOSTIC_TEST
Intervention: Cranial Accelerometry Measurement
Description: Measuring the HeadPulse using cranial accelerometry
Study: NCT02880735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ventilation.
Description: Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
Study: NCT01003340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wee Wheezers
Description: The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
Study: NCT02425969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
Study: NCT01276301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: single dose verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: single dose BI 10773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: single dose BI 10773
Study: NCT04485832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth care
Description: Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weekly CAT measurement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weekly CAT measurement
Study: NCT02936414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Accept placebo(300 mg/tid)+SGAs monotherapy.
Study: NCT04158388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-diet enriched with a higher dose of tryptophan and magnesium
Description: That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium

Intervention type: OTHER
Group type: OTHER
Intervention: Isocaloric diet
Description: That group eaten isocaloric diet plan based on Mediterranean diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: That group received moderate pressure digital manual therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo therapy
Description: That group was treated with a US (in off mode) without conductive gel.
Study: NCT01466010

Intervention type: PROCEDURE
Intervention: surgical removal of osteoid osteoma
Description: surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
Study: NCT00307437

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg
Description: Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (CNTO 1275) 45 mg
Description: Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (CNTO 1275) 90 mg
Description: Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Study: NCT00654290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone + Propranolol
Description: Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone treated 7 days pre-operation to 5 days post CABG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol from 7 days pre-operation to 5 days post CABG
Study: NCT02841163

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Chuna manipulation
Description: Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Study: NCT02748811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
Study: NCT01879930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group
Study: NCT00789737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Welchol
Description: Welchol 625mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02425969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Study: NCT00309569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 40mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 40mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubucin 60mg/m2 (only node-positive patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubucin 60mg/m2 (only node-positive patients)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT03608449

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaires
Description: questionnaire about mental health status during psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: questionnaire about mental health status during psychotherapy
Study: NCT03069859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA (1g)
Description: 1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study: NCT01626443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + D-chiro-inositol + Folic acid
Description: Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Folic acid (200 mcg); 2 x die
Study: NCT03069859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline)
Description: 0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study: NCT03002675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: exenatide (Bydureon) 2mg s.c. 1x/wk
Study: NCT02563223

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: DEVICE
Group type: OTHER
Intervention: Subject Loading System
Description: a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
Study: NCT03582540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-guidewire cannulation technique
Description: With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-guidewire cannulation technique
Description: With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
Study: NCT00415402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study: NCT03426800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and training
Description: Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
Study: NCT03779802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device programming of ABBOTT CRT pacemaker or defibrillator
Description: Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
Study: NCT00786682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Study: NCT03426800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and training
Description: Acupuncture twice in the week in 3 weeks combined with training in 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and training
Description: Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
Study: NCT01331915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theravac
Description: Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously.
Study: NCT00036738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplantation
Study: NCT00036738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT04650360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Intervention Educational Program
Description: The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
Study: NCT00724399

Intervention type: BEHAVIORAL
Intervention: Survey on womens health Issues.
Description: Cardiovascular health.
Study: NCT03471559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: single or multiple dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: single or multiple dosing
Study: NCT01521169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).
Description: 1 = Intervention with test product 1 (0,8g of plant sterol/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).
Description: 2 = Intervention with test product 2 (1,6g of plant sterol/day)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 3 - low-fat dairy fermented product (drinkable) without plant sterols.
Description: 3 = Intervention 3 (1 control product/day)